Current Neuro-Oncology
Volume
25 Number 3
15 February 2023
Home > Publications > Current Neuro-Oncology > Volume 25, Year 2023 > Number 3, 15 February
Alanen E, Heikkinen S, Nurminen R, Nykter M, Haapasalo H, Hirvonen
E, Pitkäniemi J, Rautajoki KJ.
Early-onset
grade 2-3 diffuse gliomas and schwannomas increase the risk of
central nervous system tumors among the patients'
relatives.
Neurooncol
Adv. 2023 Feb 1;5(1):vdad008∟.
doi: 10.1093/noajnl/vdad008∟.
PMID: 36950216∟.
Observational study. ˍ
Perwein T,
Giese B, Nussbaumer G, von Bueren AO, van Buiren M, Benesch M,
Kramm CM.
How
I treat recurrent pediatric high-grade glioma (pHGG): a
Europe-wide survey study.
J
Neurooncol. 2023 Feb 1∟.
doi: 10.1007/s11060-023-04241-6∟.
PMID: 36720762∟.
Observational study. ˍ
Santiago
RACB, Ali A, Ibrahim B, Mandel M, Muhsen B, Obrzut M, Ranjan S,
Borghei-Razavi H, Adada B.
Safety
of craniotomy for brain tumor resection in octogenarians and older
patients - a matched - cohort analysis.
Int
J Neurosci. 2023 Feb 1:1-7∟.
doi: 10.1080/00207454.2023.2174866∟.
PMID: 36724879∟.
Observational study˰ ˍ
Blakstad H,
Brekke J, Rahman MA, Arnesen VS, Miletic H, Brandal P, Lie SA,
Chekenya M, Goplen D.
Survival
in a consecutive series of 467 glioblastoma patients: Association
with prognostic factors and treatment at recurrence at two
independent institutions.
PLoS
One. 2023 Feb 2;18(2):e0281166∟. doi:
10.1371/journal.pone.0281166∟.
PMID: 36730349∟.
Observational study. ˍ
Bosio A,
Cerretti G, Padovan M, Caccese M, Denaro L, Chioffi F, Della Puppa
A, Aldegheri V, Guarneri V, Zagonel V, Lombardi G.
Metronomic
Temozolomide in Heavily Pretreated Patients With Recurrent
Isocitrate Dehydrogenase Wild-type Glioblastoma: A Large Real-Life
Mono-Institutional Study.
Clin
Oncol (R Coll Radiol). 2023 Feb 2:S0936-6555(23)00017-1∟.
doi: 10.1016/j.clon.2023.01.012∟.
PMID: 36858930∟.
Observational study. ˍ
Fanucci K, Pilat MJ, Shyr D, Shyr Y, Boerner S, Li J, Durecki D,
Drappatz J, Puduvalli V, Lieberman FS, Gonzalez J, Giglio P, Ivy
SP, Bindra RS, Omuro A, LoRusso P.
Multicenter
Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1-
and DH2-mutant
Glioma.
Cancer
Res Commun. 2023 Feb 2;3(2):192-201∟.
doi: 10.1158/2767-9764.CRC-22-0436∟.
PMID: 36968138∟.
Interventional study. ˍ
Giambra M, Di
Cristofori A, Conconi D, Marzorati M, Redaelli S, Zambuto M, Rocca
A, Roumy L, Carrabba G, Lavitrano M, Roversi G, Giussani C,
Bentivegna A.
Insights
into the Peritumoural Brain Zone of Glioblastoma: CDK4
and
EXT2
May Be
Potential Drivers of Malignancy.
Int
J Mol Sci. 2023 Feb 2;24(3):2835∟.
doi: 10.3390/ijms24032835∟.
PMID: 36769158∟.
Laboratory
investigation. ˍ
Douw L,
Breedt LC, Zimmermann MLM.
Cancer
meets neuroscience: the association between glioma occurrence and
intrinsic brain features.
Brain.
2023 Feb 3:awad034∟.
doi: 10.1093/brain/awad034∟.
PMID: 36732287∟.
Comment. ˍ
Refers
to:
Romero-Garcia
R, et al Transcriptomic and connectomic correlates of differential
spatial patterning among gliomas. Brain. 2022 Oct 18:awac378∟.
doi: 10.1093/brain/awac378∟.
PMID: 36256589∟.
Laboratory investigation. ˍ
Elsaka R,
Kitagwa JM, Refaat T, Mahmoud AA, Shaikh H, Meheissen MAM, Elsaid
AA.
Impact
of Extended Adjuvant Temozolamide Beyond 6 Months in the
Management of Glioblastoma Patients.
Am
J Clin Oncol. 2023 Feb 3∟.
doi: 10.1097/COC.0000000000000983∟.
PMID: 36735492∟.
Observational study. ˍ
Ma S, Patell
R, Miller E, Ren S, Marquez-Garcia J, Panoff S, Sharma R, Pinson
A, Elavalakanar P, Weber G, Uhlmann E, Neuberg D, Soman S, Zwicker
JI.
Antiplatelet
medications and intracranial hemorrhage in patients with primary
brain tumors.
J
Thromb Haemost. 2023 Feb 3:S1538-7836(23)00085-5∟.
doi: 10.1016/j.jtha.2023.01.031∟.
PMID: 36740041∟.
Observational study. ˍ
°
Ramesh KK,
Huang V, Rosenthal J, Mellon EA, Goryawala M, Barker PB, Gurbani
SS, Trivedi AG, Giuffrida AS, Schreibmann E, Han H, de le Fuente
M, Dunbar EM, Holdhoff M, Kleinberg LR, Shu HG, Shim H, Weinberg
BD.
A
Novel Approach to Determining Tumor Progression Using a Three-Site
Pilot Clinical Trial of Spectroscopic MRI-Guided Radiation Dose
Escalation in Glioblastoma.
Tomography.
2023 Feb 6;9(1):362-374∟.
doi: 10.3390/tomography9010029∟.
PMID: 36828381∟.
Interventional study. ˍ
Tonning
Olsson I, Lundgren J, Hjorth L, Munck Af Rosenschöld P,
Hammar Å, Perrin S.
Neurocognitive
development after pediatric brain tumor – a longitudinal,
retrospective cohort study.
Child
Neuropsychol. 2023 Feb 6:1-23∟.
doi: 10.1080/09297049.2023.2172149∟.
PMID: 36744788∟.
Observational study. ˍ
Calò
P, Pianton N, Basle A, Vasiljevic A, Barritault M, Beuriat PA,
Faure-Conter C, Leblond P.
Bevacizumab
as Single Agent in Children and Teenagers with Optic Pathway
Glioma.
Cancers
(Basel). 2023 Feb 7;15(4):1036∟.
doi: 10.3390/cancers15041036∟.
PMID: 36831379∟.
Observational study. ˍ
Mahase SS,
Roytman M, Roth O'Brien D, Ivanidze J, Schwartz TH, Pannullo SC,
Ramakrishna R, Magge RS, Williams N, Fine HA, Chiang GC, Knisely
JPS.
Concurrent
immunotherapy and re-irradiation utilizing stereotactic body
radiotherapy for recurrent high-grade gliomas.
Cancer
Rep (Hoboken). 2023 Feb 7:e1788∟.
doi: 10.1002/cnr2.1788∟.
PMID: 36750401∟.
Observational study. ˍ
Mani S,
Chatterjee A, Dasgupta A, Shirsat N, Epari S, Chinnaswamy G, Gupta
T.
WNT-pathway
medulloblastoma: what constitutes low-risk and how low can one
go?
Oncotarget.
2023 Feb 7;14:105-110∟.
doi: 10.18632/oncotarget.28360∟.
PMID: 36749287∟.
Laboratory
investigation. ˍ
*
Melhem JM, Tahir A, Calabrese E,
Granovskaya I, Atenafu EG, Sahgal A, Lim-Fat MJ, Perry
JR.
Dose-dependent
efficacy of bevacizumab in recurrent glioblastoma.
J
Neurooncol. 2023 Feb 7∟.
doi: 10.1007/s11060-023-04248-z∟.
PMID: 36749445∟.
Observational
study˰ ˍ
Mou B, Cruz-Lim EM.
Recurrent
Extraneural Metastatic Medulloblastoma in an Adult Presenting With
a Superscan and Treated With Radium-223.
Cureus.
2023 Feb 7;15(2):e34732∟.
doi: 10.7759/cureus.34732∟.
PMID: 36909024∟.
Case report. ˍ
*
Park J, Lee
D, Shim JK, Yoon SJ, Moon JH, Kim EH, Chang JH, Lee SJ, Kang
SG.
Mesenchymal
Stem-Like Cells Derived from the Ventricle More Effectively
Enhance Invasiveness of Glioblastoma Than Those Derived from the
Tumor.
Yonsei
Med J. 2023 Feb 7;64(3):157-166∟.
doi: 10.3349/ymj.2022.0430∟.
PMID: 36825341∟.
Laboratory investigation. ˍ
Zhang P, Duan
Y, Gu G, Qu L, Xiao D, Xi T, Pan C, Liu Y, Zhang L.
Clinical,
pathological, and radiological features of 80 pediatric diffuse
intrinsic pontine gliomas: A single-institute study.
Front
Oncol. 2023 Feb 7;13:1007393∟.
doi: 10.3389/fonc.2023.1007393∟.
PMID: 36824137∟.
Observational study. ˍ
*
Fisher PG.
When
Can We Retire 3,600 cGy Craniospinal Irradiation in
Medulloblastoma?
J
Clin Oncol. 2023 Feb 8:JCO2300008∟.
doi: 10.1200/JCO.23.00008∟.
PMID: 36753694∟.
Editorial. ˍ
Refers
to:
Coltin
H, et al., The Burden of Surviving Childhood Medulloblastoma: A
Population-Based, Matched Cohort Study in Ontario, Canada. J Clin
Oncol. 2023 Jan 25:JCO2202466∟.
doi: 10.1200/JCO.22.02466∟.
PMID: 36696605∟.
Observational study˰ ˍ
van der Meer P, Dirven L, Fiocco M,
Vos MJ, Kouwenhoven MCM, van den Bent MJ, Taphoorn MJB, Koekkoek
JAF.
Effectiveness
of Antiseizure Medication Triple Therapy in Glioma Patients With
Refractory Epilepsy: An Observational Cohort Study.
Neurology.
2023 Feb 8:10.1212/WNL.0000000000206852∟.
doi: 10.1212/WNL.0000000000206852∟.
PMID: 36754633∟.
Observational
study. ˍ
Zhang C, Deng
Z, Yang Z, Xie J, Hou Z.
A
nomogram model to predict the acute venous thromboembolism risk
after surgery in patients with glioma.
Thromb
Res. 2023 Feb 9;224:21-31∟.
doi: 10.1016/j.thromres.2023.02.002∟.
PMID: 36805800∟.
Observational study˰ ˍ
Liu Y, Sun P,
Zhou M, Du J, Zeng G.
Pediatric
spinal cord diffuse midline glioma with H3 K27M-alteration with
leptomeningeal dissemination: a rare case with intracranial
hypertension onset and no spinal cord-related symptom.
Childs
Nerv Syst. 2023 Feb 10∟.
doi: 10.1007/s00381-023-05851-1∟.
PMID: 36759369∟.
Case report˰ ˍ
Uetani H, Azuma M, Khant ZA, Watanabe Y, Kudo K, Kadota Y,
Yokogami K, Takeshima H, Kuroda JI, Shinojima N, Hamasaki T,
Mukasa A, Hirai T.
Importance of Age
and Noncontrast-Enhancing Tumor as Biomarkers for Isocitrate
Dehydrogenase-Mutant Glioblastoma: A Multicenter Study.
J
Comput Assist Tomogr. 2023 Feb 10∟.
doi: 10.1097/RCT.0000000000001456∟.
PMID: 36877775∟.
Observational study. ˍ
Winnicki C,
Leblond P, Bourdeaut F, Pagnier A, Paluenzela G, Chastagner P,
Duhil-De Benaze G, Min V, Sudour-Bonnange H, Piette C, Entz-Werle
N, Chabaud S, André N.
Retrospective
National "Real Life" Experience of the SFCE with the
Metronomic MEMMAT and MEMMAT-like Protocol.
J
Clin Med. 2023 Feb 10;12(4):1415∟.
doi: 10.3390/jcm12041415∟.
PMID: 36835950∟.
Observational study. ˍ
Van Gool SW,
Makalowski J, Van de Vliet P, Van Gool S, Sprenger T, Schirrmacher
V, Stuecker W.
Individualized
Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A
Single Institute Experience.
Cancers
(Basel). 2023 Feb 13;15(4):1194∟.
doi: 10.3390/cancers15041194∟.
PMID: 36831536∟.
Observational study. ˍ
Yahia-Cherif M, Luce S, De Witte O,
Sadeghi-Meibodi N, Leurquin-Sterk G, Lefranc F.
Late-line
treatment with bevacizumab alone or in combination with
chemotherapy in recurrent high-grade gliomas.
Acta
Neurochir (Wien). 2023 Feb 13∟.
doi: 10.1007/s00701-023-05524-7∟.
PMID: 36781461∟.
Observational
study˰ ˍ
Faghihjouibari
M, Khadivi M, Rouhani R, Pazoki Toroudi H, Nazari M, Sadeghian M,
Abolfazli M.
Comparison
of Efficacy and Safety of Levetiracetam Versus Phenytoin for
Post-craniotomy Seizure Prophylaxis.
Med
J Islam Repub Iran. 2023 Feb 14;37:7∟.
doi: 10.47176/mjiri.37.7∟.
PMID: 37123333∟.
Observational
study. ˍ
Renovanz M, Kurz SC, Rieger J, Walter B, Becker H, Hille H,
Bombach P, Rieger D, Grosse L, Häusser L, Skardelly M, Merk
DJ, Paulsen F, Hoffmann E, Gani C, Neumann M, Beschorner R, Rieß
O, Roggia C, Schroeder C, Ossowski S, Armeanu-Ebinger S, Gschwind
A, Biskup S, Schulze M, Fend F, Singer S, Zender L, Lengerke C,
Brucker SY, Engler T, Forschner A, Stenzl A, Kohlbacher O, Nahnsen
S, Gabernet G, Fillinger S, Bender B, Ernemann U, Öner Ö,
Beha J, Malek HS, Möller Y, Ruhm K, Tatagiba M, Schittenhelm
J, Bitzer M, Malek N, Zips D, Tabatabai G.
Clinical
outcome of biomarker-guided therapies in adult patients with
tumors of the nervous system.
Neurooncol
Adv. 2023 Feb 14;5(1):vdad012∟.
doi: 10.1093/noajnl/vdad012∟.
PMID: 36915613∟.
Interventional study. ˍ
*
Ubaldi L,
Saponaro S, Giuliano A, Talamonti C, Retico A.
Deriving
quantitative information from multiparametric MRI via Radiomics:
Evaluation of the robustness and predictive value of radiomic
features in the discrimination of low-grade versus high-grade
gliomas with machine learning.
Phys
Med. 2023 Feb 14;107:102538∟.
doi: 10.1016/j.ejmp.2023.102538∟.
PMID: 36796177∟.
Observational study˰ ˍ
Bagley SJ.
Phase 2 trials in the era of
glioblastoma immunotherapy: New mechanisms of action, familiar
challenges in trial design and tumor response assessment.
Neuro
Oncol. 2023 Feb 15:noad043∟.
doi: 10.1093/neuonc/noad043∟.
PMID: 36789741∟.
Editorial˰ ˍ
REFERS
TO:
°Sampson
JH, et al.,Targeting
the IL4 Receptor with MDNA55 in Patients with Recurrent
Glioblastoma: Results of a Phase 2b Trial. Neuro
Oncol. 2023 Jan 14:noac285∟.
doi: 10.1093/neuonc/noac285∟.
PMID: 36640127∟.
Interventional study. ˍ
Bărăian
AI, Iacob BC, Sorițău O, Tomuță I, Tefas LR,
Barbu-Tudoran L, Șușman S, Bodoki E.
Ruxolitinib-Loaded
Imprinted Polymeric Drug Reservoir for the Local Management of
Post-Surgical Residual Glioblastoma Cells.
Polymers
(Basel). 2023 Feb 15;15(4):965∟.
doi: 10.3390/polym15040965∟.
PMID: 36850247∟.
Laboratory investigation. ˍ
Haskell-Mendoza
AP, Srinivasan ES, Lerner EC, Edwards RM, Schwalb AM, Jackson JD,
Hardigan AA, Vaios EJ, Fecci PE.
Risk
of Tract Seeding Following Laser Interstitial Thermal Therapy for
Brain Tumors.
Neurosurgery.
2023 Feb 15∟.
doi: 10.1227/neu.0000000000002403∟.
PMID: 36790207∟.
Observational study˰ ˍ
°
Lepski G,
Bergami-Santos PC, Pinho MP, Chauca-Torres NE, Evangelista GCM,
Teixeira SF, Flatow E, de Oliveira JV, Fogolin C, Peres N, Arévalo
A, Alves VAF, Barbuto JAM.
Adjuvant
Vaccination with Allogenic Dendritic Cells Significantly Prolongs
Overall Survival in High-Grade Gliomas: Results of a Phase II
Trial.
Cancers
(Basel). 2023 Feb 15;15(4):1239∟.
doi: 10.3390/cancers15041239∟.
PMID: 36831580∟.
Interventional
study. ˍ
Pasqualetti F, Zanotti S.
Nonrandomised
controlled trial in recurrent glioblastoma patients: the promise
of autologous tumour lysate-loaded dendritic cell vaccination.
Br
J Cancer. 2023 Feb 15∟.
doi: 10.1038/s41416-023-02194-1∟.
PMID: 36792723∟.
Comment. ˍ
Refers
to:
°Liau
LM, et al., Association
of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With
Extension of Survival Among Patients With Newly Diagnosed and
Recurrent Glioblastoma: A Phase 3 Prospective Externally
Controlled Cohort Trial. JAMA Oncol. 2022 Nov 17∟.
doi: 10.1001/jamaoncol.2022.5370∟.
PMID: 36394838∟.
Interventional study. ˍ